{
  "compound": "Nabiximols",
  "condition": "MULTIPLE_SCLEROSIS",
  "effect_size": "Large for physical (d = 0.82), medium for mental (d = 0.58)",
  "study_type": "OBSERVATIONAL",
  "source": "NORML:MS_OBSERVATIONAL_003",
  "participants": "892 MS patients across 5 European countries",
  "year": 2016,
  "notes": "Quality of Life Impact of Nabiximols in MS: Multinational Survey",
  "confidence": "medium",
  "abstract": "Nabiximols users: MSQoL-54 physical composite 12.4 points higher; mental composite 8.7 points higher; 74% reported improved QoL"
}